Üveitlerin Tedavisinde Posterior Subtenon Triamsinolon Kullanımının Etkinliği ve Komplikasyonları

March 2007
Retina-Vitreus/Journal of Retina-Vitreous;Mar2007, Vol. 15 Issue 1, p35
Academic Journal
Purpose: To analyze the efficacy and complications of posterior subtenon triamcinolone injection (PSTT) for the treatment of uveitis. Materials and Methods: The data from the medical records of the cases with non-infectious uveitis treated with PSTT injection were examined retrospectively. Efficacy of PSTT injection for vitritis, retinal vasculitis or cystoid macular edema (CME) and complications including intraocular pressure (IOP) elevation and cataract progression were evaluated. Efficacy of PSTT was defined as a decrease in vitreous haze for vitritis, 50% or more decrease in central foveal thickness in optical coherence tomographic measurement together with fundoscopic or angiographic improvement for CME and clinical or angiographic improvement in vascular leakage for vasculitis. Paired t-test and Wilcoxon test were performed for statistical analysis. Results: A total of 50 eyes of 38 cases were included in this study. The mean follow-up time was 16.3 months (1-60). The mean visual acuity (VA) was 0.42 before the injections, and it significantly increased during 1st, 3rd, and 6th month follow-ups (p<0.05). Overall clinical efficacy was 78% in the first 3 months. The efficacy of the treatment at the 1st and the 3rd months were 97%-78% for vitritis, 77%-73% for CME, and 64%-81% for vasculitis respectively. Significant IOP elevation (>21mmHg) was observed in 24%, and cataract progression in 22. 8% of the eyes. Conclusion: PSTT treatment is an effective and safe method for controlling posterior segment inflammation of noninfectious uveitis. The most important advantage is being deprived of systemic side effects of steroids.


Related Articles

  • Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection. Shulman, S.; Ferencz, J. R.; Gilady, G.; Ton, Y.; Assia, E. // Eye;Aug2007, Vol. 21 Issue 8, p1067 

    PurposeIn some patients with macular oedema, intravitreal triamcinolone acetonide injection (IVTA) fails to improve visual acuity, although oedema shows clinical and angiographic improvement. Side effects can include increased intraocular pressure, cataract development, and (rarely)...

  • Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Jonas, J B; Schlichtenbrede, F // Eye;Jul2008, Vol. 22 Issue 7, p869 

    Purpose: Within the last 5 years, intravitreal injections of triamcinolone acetonide have been for a wide variety of ocular diseases with intraocular oedema and neovascularization. With clinical experience accumulating, the question arises for which indication the side effects outweigh the...

  • Interpreting the Science of the DRCR.net and Other Clinical Trials on the Treatment of DME. Klancnik Jr., James M. // Ocular Surgery News;4/10/2012 Supplement, p7 

    The article discusses clinical trials on the treatment of diabetic macular edema (DME). Treatment goals include resolving the edema, improving vision, and preventing its recurrence. Major trials such as the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective...

  • Eye Health.  // Townsend Letter for Doctors & Patients;Dec2004, Issue 257, p24 

    Focuses on the value of nutritional supplements for maintaining eye health in the U.S. Benefits of vitamins in reducing the incidence of advanced-stage age-related macular degeneration among persons at high risk for the disease; Means of reducing the formation of some types of cataracts;...

  • Severe intraocular pressure rise following intravitreal triamcinolone: a national survey to estimate incidence and describe case profiles. Ionides, Alex // Current Medical Literature: Ophthalmology;2014, Vol. 24 Issue 3, p95 

    The article reviews a research study published in a 2014 issue of the journal "Eye" which found the incidence of a severe rise in intraocular pressure (IOP) following intravitreal triamcinolone.

  • Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Islam, M. S.; Vernon, S. A.; Negi, A. // Eye;Mar2007, Vol. 21 Issue 3, p321 

    PurposeTo determine the incidence of cataract following intravitreal triamcinolone (IVTA) for diabetic macular oedema.MethodsProspective, non-randomised, interventional cohort case series. A total of 27 eyes of 27 patients with diabetic macular oedema received an intravitreal injection of 4 mg...

  • Primary versus secondary intraocular lens implantation in the management of congenital cataract. Mohamed, Thanaa H.; Eldin Zaki, Rania G.; Hashem, Mohamed H. // Journal of Egyptian Ophthalmological Society;Jun2016, Vol. 10 Issue 2, p54 

    Aim This study aimed to compare the efficacy of primary intraocular lens (IOL) implantation following removal of congenital cataract in patients with aphakia younger than 2 years of age, followed by secondary implantation after the age of 2 years. Patients and methods This was a comparative...

  • Results of cataract surgery in the very elderly population. Michalska-Małecka, Katarzyna; Nowak, Mariusz; Gościniewicz, Piotr; Karpe, Jacek; Słowińska-Łożyńska, Ludmiła; Łypaczewska, Agnieszka; Romaniuk, Dorota // Clinical Interventions in Aging;Aug2013, Vol. 8, p1041 

    Aim: The aim of our study was to retrospectively evaluate the effectiveness and safety of cataract surgery and intraocular lens implantation (IOL) for patients aged 90 years or older, whom we define as "very elderly." Methods: The study involved a total number of 122 patients (122 eyes) with...

  • Current trends in the pharmacotherapy of diabetic retinopathy. Kumar, B.; Gupta, S. K.; Saxena, R.; Srivastava, S. // Journal of Postgraduate Medicine;Apr-Jun2012, Vol. 58 Issue 2, p132 

    Diabetic retinopathy (DR) is one of the most debilitating disorders of microvasculature of the retina and one of the leading causes of vision loss among the working class worldwide. At present, intravitreal anti-inflammatory (corticosteroids) and anti-angiogenesis (anti-Vascular Endothelial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics